{
  "id": "bfef5d2bcc33bc2d",
  "title": "The New England Journal of Medicine Publishes Results from Phase 1 / 2 MARINA\u00ae Trial of Delpacibart Etedesiran ( del - desiran ) for Treatment of Myotonic Dystrophy Type 1",
  "description": "20260218T230000Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-results-from-phase-12-marina-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1-302692044.html",
  "published_at": "20260218T230000Z",
  "fetched_at": "2026-02-19T00:30:34.211663+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-results-from-phase-12-marina-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1-302692044.html",
    "url_mobile": "",
    "title": "The New England Journal of Medicine Publishes Results from Phase 1 / 2 MARINA\u00ae Trial of Delpacibart Etedesiran ( del - desiran ) for Treatment of Myotonic Dystrophy Type 1",
    "seendate": "20260218T230000Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}